Cargando…
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP
Asubset of patients with advanced-stage classical Hodgkin lymphoma (cHL) relapse or progress following standard treatment. Given their dismal prognosis, identifying this group of patients upfront represents an important medical need. While prior research has identified characteristics of the tumor m...
Autores principales: | Jachimowicz, Ron Daniel, Pieper, Luise, Reinke, Sarah, Gontarewicz, Artur, Plütschow, Annette, Haverkamp, Heinz, Frauenfeld, Leonie, Fend, Falko, Overkamp, Mathis, Jochims, Franziska, Thorns, Christoph, Leo Hansmann, Martin, Möller, Peter, Rosenwald, Andreas, Stein, Harald, Reinhardt, Hans Christian, Borchmann, Peter, von Tresckow, Bastian, Engert, Andreas, Klapper, Wolfram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168506/ https://www.ncbi.nlm.nih.gov/pubmed/32381573 http://dx.doi.org/10.3324/haematol.2019.243287 |
Ejemplares similares
-
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
por: Jachimowicz, Ron D., et al.
Publicado: (2021) -
P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
por: Grund, Johanna, et al.
Publicado: (2022) -
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
por: Damaschin, Carla, et al.
Publicado: (2021) -
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
por: Garcia-Marquez, Maria A., et al.
Publicado: (2021) -
P016: Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)
por: Dragičević, Ida Hude, et al.
Publicado: (2022)